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Immunology has become as an attractive discipline of biomedical science in the 21st century, integrated with the rapid develop-
ment of molecular biology, cell biology, structural biology, genetics and other branches in life sciences. A special issue of Sci 
China Life Sci was published in February 2010 to highlight recent progresses in immunology. Six review articles focusing on 
various specific topics were contributed by leading scientists who work in respective fields of immunology. Some progresses of 
immunology research in China are also described. 
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Immunity, the concept from immunis, a Latin word meaning 
“exempt”, can be traced back to the plaque of Athens in 430 
BC. Many other ancient nations have documented that peo-
ple who had recovered from a previous bout of the disease 
would acquire mysterious ability to avoid contracting the 
illness for the second time. Early forms of vaccination were 
developed long before the word vaccination was first intro-
duced by Edward Jenner in 1796 to specifically describe the 
injection of smallpox vaccine, but it was not until the 19th 
and 20th centuries before the concept developed into scien-
tific theory [1]. In the 21st century, immunology has be-
come an indispensable branch of biomedical science that 
covers the study of all aspects of the immune system, and 
broadened its horizons with much research being performed 
in the more specialized niches, such as clinical immunology, 
developmental immunology, evolutionary immunology, 
cancer immunology and immunotherapy. Immunology deals 
with not only functioning of the immune system in health 
state, but malfunctions of the immune system in immuno-
logical disorders as well, thus deepening understanding of 
pathophysiology of human diseases and contributing to 
therapeutical and pharmaceutical developments.  
To celebrate the 60th anniversary of Science China Press, 
a special issue of Sci China Life Sci summarizing recent 
advances in immunology came out in February 2010. Au-
thors of the 6 review articles published on that issue, who 
are all leading immunologists, shared their understanding on 
different hot questions or focused on a single question of 
common interest from different views arisen from their re-
spective expertise.  
Vertebrates have evolved to protect themselves against 
infections by two different means: innate immunity and 
adaptive immunity, while invertebrates rely on innate im-
munity only. Both immune responses are tightly regulated 
in all organisms to prevent over-reaction and maintain im-
munological homeostasis [2–4]. In 1989, Janeway proposed 
a revolutionary concept that adaptive immunity is initiated 
by pattern recognition of innate immunity [5]. In a mini-
review article published on the special issue of immunology, 
Liu et al. [6] provided the first experimental evidence that 
microbial recognition by the innate immune system turns on 
the adaptive immune system and explained how the immune 
system controls the balance between sensing pathogen-  
associated molecular patterns (PAMPs) and the self-danger- 
associated molecular patterns (DAMPs). Their previous 
work demonstrated the existence of costimulatory activity 
of bacterial components and the need of cis-presentation of 
both antigen and costimulartors for T cell activation [7,8]. 
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The recent observation on the role of the CD24-SiglecG/10 
pathway in repressing tissue injures indicates that this novel 
pathway very likely differentially regulate the recognition 
of DAMPs and PAMPs. Either SiglecG identified in mice or 
Siglec10 in human forms complexes with high mobility 
group protein-1 (HMGB1), an intracellular component able 
to induce inflammatory responses, through CD24, and neg-
atively regulates DAMPs only in vivo. 
Despite the protective role of the inflammatory response 
essential to the host, the response must be actively termi-
nated after the acute phase. Failure to do so results in “by-
stander” damage to tissues and autoimmunity diseases. Re-
cent studies have revealed that adaptive immune cells ac-
tively dampen initial innate response, as a mean of negative 
regulation on the inflammatory response. Tang et al. [9] 
summarized novel findings in this regard in another review 
article. It has become clear that conventional T cells not 
only activate innate cells to clear pathogens, but surprising-
ly take part in regulation of the innate immune response 
during the early phases of infection. There is an increasing 
body of evidence indicating that regulatory T cells (Treg), a 
subset of CD4+ T cells, can suppress functions of not only 
effector T cells but also innate cells [10–12]. A recent find-
ing suggests an interesting feedback mechanism that allows 
T cells to selectively eliminate the bystander effect of the 
inflammatory response [13]. Both effector and memory T 
cells suppress potentially damaging inflammation through 
dampening the hyperactive inflammasome, yet leave the 
primary inflammatory response intact on the onset of im-
munity. The authors speculate that a feedback loop from the 
adaptive to the innate immune system was evolved in verte-
brates whose innate inflammatory response might be insuf-
ficient to meet all the requirements.  
The T cell pathways play a central role in regulating the 
immune response. Accumulating evidences indicate that the 
interaction of T-cell receptor (TCR) with antigenic pep-
tide/major histocompatibility complex (MHC) alone is not 
sufficient to drive the activation of naive T cells leading to 
optimal immue responses [14]. A group of “costimulatory 
molecules” present on cell surface have been identified to 
actively suppress T cell responses in the presence of TCR 
signal [15]. Wang et al. [16], who discovered various cost-
imulatory and coinhibitory molecules in T cell activation, 
reviewed the recent studies on two major families involved 
in T cell costimulation and regulation of adaptive immunity 
from perspective of structural immunology. The most ex-
tensively investigated receptors expressed on T cells and 
ligands expressed on the antigen-presenting cells or periph-
eral tissues include the members of the B7/CD28 and tu-
mor-necrosis factor (TNF)/TNFR families. Molecular 
polymerization state and module organization of all these 
receptors and ligands are schematically represented in this 
review chapter, with detailed description of domain struc-
tures. Physiological function of each family member and 
therapeutic application of the B7-CD28/CTLA-4 and the 
B7-H1/B7-DC/PD-1 pathways are well summarized as well. 
In the future, more structural information providing deeper 
insight into T cell costimulation will provide a sound basis 
for better studying the biological functions of the costimu-
latory pathways and encourage their application in therapy. 
Tumor necrosis factor receptor-associated factors (TRAF) 
were initially discovered as adaptor proteins that couple the 
tumor necrosis factor receptor (TNFR) family to signaling 
pathways. More recently they have also been shown to be 
signal transducers of a large number of receptor families 
including the TNF receptor family and the Toll-like recep-
tors-interleukin-1 receptors (TLR-IL-1R) family. Wang et  
al. [17] contributed to a minute review regarding the struc-
ture and function of the TRAF family. All the 6 members of 
the TRAF family share a C-terminal homology region 
termed the TRAF domain that is capable of binding to the 
cytoplasmic domain of receptors, and to other TRAF pro-
teins. The 3D structures of the TRAF domain and another 
N-terminal RING domain are detailedly described in this 
article. Research studies in the past few years have estab-
lished the central role of the TRAF proteins in inflammation 
and immunity by regulating both canonical and noncanoni-
cal nuclear factor B (NF-B) pathways as well as type 1 
interferons production. Tremendous progresses have been 
made recently, for instance, the recruitment of TRAF2/5 in 
a signaling complex mediating the TNF-induced canonical 
NF-B activation [18]; the oligomerization of TRAF6 to 
activate its E3 ubiquitin ligase activity, further leading to 
transforming growth factor -activated kinase 1 (TAK1) 
and downstream signal transduction in the TLR-IL-1R-  
induced canonical NF-B pathway [19]; and the degrada-
tion of TRAF2 and TRAF3 resulting in the stabilization and 
accumulation of NF-B-inducing kinase (NIK) in non-
canonical NF-B pathway [20,21]. Notwithstanding, many 
aspects about the roles played by the TRAF family in 
NF-B remain unclear and require more investigations.  
Dendritic cells (DCs) are professional antigen-presenting 
cells within the immune system, crucial for the innate and 
adaptive immune responses to infections. Plasmacytoid 
dendritic cells (pDCs), an important type of dendritic cells, 
represent a unique and crucial immune cell population ca-
pable of producing type I interferons (IFNs) in response to 
viral infection [22]. Tang et al. [23] working in the labora-
tory from which pDCs were indentified 10 year ago, dedi-
cated another chapter by reviewing the remarkable progress 
within the past decade in understanding pDC biology, with 
focusing on the molecular mechanisms in antiviral immuni-
ty and autoimmunity [23]. Cellular properties, including the 
morphology, surface phenotype, development, location and 
migration of human pDCs are recounted in the first part, 
while physiological and pathophysiological functions of 
pDCs in both antiviral immunity and autoimmunity are nar-
rated in the following part. Increasingly available data sug-
gest that pDCs sense nucleic acids through TLR7 and TLR9, 
3892 Liu W   Chinese Sci Bull   December (2011) Vol.56 No.35 
two members of the Toll-like receptor family [24,25], and 
link innate and adaptive immunity by promoting the antivi-
ral functions of myeloid dendritic cells (mDCs), natural 
killer (NK) cells, T cells and B cells [26]. Considerable 
emerging evidences argue that the chronically activated 
pDCs and the IFN- that they produce in response to self 
DNA/RNA are contributing factors in the pathogenesis of 
some autoimmune diseases, such as systemic lupus erythe-
matosus (SLE) and psoriasis. Despite greatly enhanced un-
derstanding of pDC biology achieved recently, a number of 
fascinating questions requiring further investigation are cru-
cial to develop safe and effective immunotherapy for viral 
infectious diseases and autoimmune diseases.  
For better understanding human diseases without the 
added risk of causing harm to an actual human being during 
the process, modeling diseases on animals is an irreplacea-
ble approach. Zhang et al. [27] reviewed the establishment 
of a new generation of humanized mice, an animal model 
for studying HIV-1 immuno-pathogenesis. They propose 
that the criteria of a robust animal model for “hypothe-
sis-testing/mechanistic” research in human immunology and 
immuno-pathology should be: (1) it has well studied 
hemato-lymphoid organs and target cells similar to those of 
humans; (2) the human pathogens establish infection and 
lead to relevant diseases; and (3) it is genetically inbred and 
can be manipulated via genetic, immunological and phar-
macological means. Unfortunately, some immunological 
findings in mice cannot translate directly to the human im-
mune system and many human pathogens infect human 
cells only. Significant improvements have been achieved 
recently in humanized mouse models that to some extent 
overcome these limitations. Three mouse models commonly 
used in current research of human immune system and 
HIV-1 diseases are introduced in detail in this article, and 
novel mechanistic understanding gained from latest studies 
on HIV-1 infection and pathogenesis using NTB-hu HSC 
mice is summarized at length as well. Some featured events 
during clinical latency prior to AIDS developing, such as 
drop of both CD4+ and CD8+ T cells, depletion of 
CCR5+CD4+ memory T cells in the gut-associated lymphoid 
tissue (GALT), and elevated/reduced level of regulatory T 
(Treg) cells in infectious diseases and autoimmune diseases 
respectively, have been able to be scrutinized using appro-
priate mouse models. In the future, it will be exciting to 
model directed human tissue-specific differentiation in hu-
manized mice. 
In the past decade, Chinese scientists working in domes-
tic institutes have achieved fruitful outcome in immunity 
studies, coincident with the giant economic development 
occurring in China. More and more young talented immu-
nologists have been attracted by lots of newly established 
laboratories. Longing for comprehensive and deeper mech-
anistic understanding of human pathology form irresistible 
impetus; revolutionary advances of biotechnology, e.g. gene 
knockout and RNAi knockdown, provide significant tech-
nical support; and increasing funding resources in China 
establish solid material basis for current immunology re-
search. Noteworthy contributions made by Chinese labora-
tories in 2009 and 2010 include monoclonal antibodies 
production [28–31], studies on antigen-antibody binding 
site [32,33], Toll-like receptor (TLR) mediated signaling 
pathways [34,35], inflammasome and inflammatory re-
sponse [36–38], and HIV-1 infection [39,40]. Owing to 
constant and steady increase of funding resources as well as 
progressively improved research conditions, more signifi-
cant achievements generated in domestic laboratories in 
China are highly expected. 
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